Search

IMMUNE DYNAMICS IN RESPONSE TO PD-1 BLOCKADE IN MURINE ORAL CAVITY CANCER

Immunotherapy / Systemic Therapy

Katherine C Wai, MD; Lauren S Levine, MD; Iliana Tenvooren, MS; Patrick K Ha, MD; Mekhail Anwar, MD, PhD; Matthew H Spitzer, PhD

University of California San Francisco

BLOOD EOSINOPHIL COUNT MAY PREDICT SEVERE IMMUNE-RELATED ADVERSE EVENTS DUE TO NIVOLUMAB IN RECURRENT OR METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA

Immunotherapy / Systemic Therapy

Yushi Ueki, MD, PhD; Takeshi Takahashi, MD; Ryusuke Shodo, MD, PhD; Keisuke Yamazaki, MD, PhD; Arata Horii, MD, PhD

Department of Otolaryngology Head and Neck Surgery Niigata University Faculty of Medicine

REAL WORLD OUTCOMES IN PATIENTS WITH HNSCC TREATED WITH CHECKPOINT INHIBITION

Immunotherapy / Systemic Therapy

Sara B Hobday¹; Robert M Brody, MD¹; Barry A Kriegsman, MD, PhD¹; Devraj Basu, MD, PhD, FACS²; Jason Newman, MD, FACS¹; Roger B Cohen, MD³; Abigail Doucette⁴; Lova Sun, MD, MSCE⁵

¹Department of Otorhinolaryngology: Head and Neck Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; ²Department of Otorhinolaryngology: Head and Neck Surgery, Perelman School of Medicine, University of Pennsylvania, The Wistar Institute, Philadelphia, PA; ³Abramson Cancer Center of the University of Pennsylvania, Philadelphia PA; ⁴Department of Radiation Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia PA; ⁵Division of Hematology/Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA

RACIAL REPRESENTATION IN CLINICAL TRIALS OF IMMUNE CHECKPOINT INHIBITORS IN HEAD AND NECK CANCER

Immunotherapy / Systemic Therapy

Grace M Amadio, BS¹; Anita Sulibhavi, MD²; Olivia Given Costello, MLIS³; Jeffrey C Liu, MD²

¹Lewis Katz School of Medicine at Temple University; ²Department of Otolaryngology, Head and Neck Surgery, Temple University, Philadelphia, PA; ³Charles Library, Temple University

COMPUTATIONAL AND IN VITRO EVALUATION OF SHARED IMMUNOGENIC NEOANTIGENS IN ADENOID CYSTIC CARCINOMA

Immunotherapy / Systemic Therapy

James A Cevallos, MS¹; Catherine Y Han, BS²; Fengshen Kuo, PhD³; Jingming Wang, PhD³; Zaineb Nadeem, MS³; Patrick Ha, MD¹; Luc Morris, MD, MSc³

¹UCSF; ²Weill Cornell Medicine; ³Memorial Sloan Kettering Cancer Center

ONCOLOGIC QUALITY METRICS IN PATIENTS WITH OPERABLE MUCOSAL HEAD AND NECK SQUAMOUS CELL CARCINOMA ENROLLED IN NEOADJUVANT TARGETED THERAPY TRIALS

Immunotherapy / Systemic Therapy

Marco A Mascarella, MD; Varun Vendra; Mark W Kubik; Shaum Sridharan; Seungwon Kim; Robert L Ferris; Moon J Fenton; James P Ohr; Dan P Zandberg; Umamaheswar Duvvuri

University of Pittsburgh Medical Center

NEUTROPHIL TO LYMPHOCYTE RATIO AND PERIPHERAL BLOOD BIOMARKERS CORRELATE WITH OUTCOMES AMONG PATIENTS WITH RECURRENT METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA AND SALIVARY GLAND CANCER TREATED ON A PHASE II TRIAL OF PEMBROLIZUMAB AND VORINOSTAT

Immunotherapy / Systemic Therapy

Cassie Pan¹; Qian (Vicky) Wu²; Jenna Voutsinas²; Jeffrey J Houlton¹; Brittany Barber¹; Neal Futran¹; Renato G Martins³; Jonathan R Fromm⁴; Cristina P Rodriguez³

¹Department of Otolaryngology, University of Washington, Seattle, WA; ²Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA; ³Division of Oncology, Department of Medicine, University of Washington, Seattle, WA; ⁴Department of Laboratory Medicine, University of Washington, Seattle, WA

EFFECT OF PREOPERATIVE IMMUNOTHERAPY ON COMPLICATIONS AFTER HEAD AND NECK SURGERY

Immunotherapy / Systemic Therapy

Ramez Philips, MD; Angela Alnemri; Adam Luginbuhl, MD; David Cognetti, MD; Joseph Curry, MD

Thomas Jefferson University Hospitals